RS53782B1 - Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera - Google Patents

Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera

Info

Publication number
RS53782B1
RS53782B1 RS20150094A RSP20150094A RS53782B1 RS 53782 B1 RS53782 B1 RS 53782B1 RS 20150094 A RS20150094 A RS 20150094A RS P20150094 A RSP20150094 A RS P20150094A RS 53782 B1 RS53782 B1 RS 53782B1
Authority
RS
Serbia
Prior art keywords
peptide
cancer
tumor
cells
peptides
Prior art date
Application number
RS20150094A
Other languages
English (en)
Serbian (sr)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of RS53782B1 publication Critical patent/RS53782B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
RS20150094A 2008-10-01 2008-10-01 Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera RS53782B1 (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

Publications (1)

Publication Number Publication Date
RS53782B1 true RS53782B1 (sr) 2015-06-30

Family

ID=40342382

Family Applications (12)

Application Number Title Priority Date Filing Date
RS20150094A RS53782B1 (sr) 2008-10-01 2008-10-01 Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
RS20161019A RS55543B1 (sr) 2008-10-01 2008-10-13 Nova imunoterapija protiv nekoliko tumora uključujući neuronalne tumore i tumore mozga
RS20161160A RS55531B1 (sr) 2008-10-01 2009-09-28 Smeša tumor-asociranih peptida i srodnih antitumorskih vakcina za lečenje glioblastoma (gbm) i drugih malignih tumora
RS20160553A RS55043B1 (sr) 2008-10-01 2009-09-28 Smeša koja sadrži tumor-asocirane peptide i vakcina za lečenje glioblastoma i drugih malignih tumora
RS20200085A RS60006B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RS20181585A RS58229B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora uključujući tumor neurona i tumore mozga
RS20200512A RS60338B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RS20200692A RS60385B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumoreneurona i mozga
RS20200693A RS60386B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RS20200691A RS60381B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RS20190118A RS58443B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora uključujući tumor neurona i tumore mozga
RS20200973A RS60656B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga

Family Applications After (11)

Application Number Title Priority Date Filing Date
RS20161019A RS55543B1 (sr) 2008-10-01 2008-10-13 Nova imunoterapija protiv nekoliko tumora uključujući neuronalne tumore i tumore mozga
RS20161160A RS55531B1 (sr) 2008-10-01 2009-09-28 Smeša tumor-asociranih peptida i srodnih antitumorskih vakcina za lečenje glioblastoma (gbm) i drugih malignih tumora
RS20160553A RS55043B1 (sr) 2008-10-01 2009-09-28 Smeša koja sadrži tumor-asocirane peptide i vakcina za lečenje glioblastoma i drugih malignih tumora
RS20200085A RS60006B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RS20181585A RS58229B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora uključujući tumor neurona i tumore mozga
RS20200512A RS60338B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RS20200692A RS60385B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumoreneurona i mozga
RS20200693A RS60386B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RS20200691A RS60381B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RS20190118A RS58443B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora uključujući tumor neurona i tumore mozga
RS20200973A RS60656B1 (sr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga

Country Status (24)

Country Link
US (19) US8119139B2 (enExample)
EP (12) EP2172211B1 (enExample)
JP (10) JP5855940B2 (enExample)
KR (6) KR102392070B1 (enExample)
CN (3) CN102170900B (enExample)
AU (2) AU2009300088B2 (enExample)
BR (2) BRPI0920759A2 (enExample)
CA (9) CA2936982C (enExample)
CY (11) CY1116302T1 (enExample)
DK (12) DK2172211T3 (enExample)
EA (3) EA023378B1 (enExample)
ES (12) ES2536465T3 (enExample)
HR (12) HRP20160915T1 (enExample)
HU (11) HUE031030T2 (enExample)
LT (10) LT2172212T (enExample)
MX (3) MX2011003540A (enExample)
NZ (4) NZ603016A (enExample)
PL (12) PL2172211T3 (enExample)
PT (12) PT2172211E (enExample)
RS (12) RS53782B1 (enExample)
SI (12) SI2172211T1 (enExample)
TR (2) TR201900809T4 (enExample)
UA (3) UA110599C2 (enExample)
WO (2) WO2010037514A2 (enExample)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012079878A2 (en) * 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
RS54147B1 (sr) * 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012027379A2 (en) 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
WO2013052158A2 (en) * 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
ES2856091T3 (es) * 2011-09-14 2021-09-27 Univ Northwestern Nanoconjugados capaces de atravesar la barrera hematoencefálica
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2804602B1 (en) * 2012-01-20 2024-12-04 Del Mar Pharmaceuticals Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
SMT202100545T1 (it) 2012-05-16 2021-11-12 Stemline Therapeutics Inc Vaccini contro il cancro mirati alle cellule staminali cancerose
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
SI3456339T1 (sl) * 2013-08-05 2022-01-31 Immatics Biotechnologies Gmbh Nova imunoterapija proti več tumorjem, kot je pljučni rak, vključno z nedrobnoceličnim pljučnim rakom
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CA2946552A1 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
PL3689899T3 (pl) 2014-04-25 2022-01-31 2Seventy Bio, Inc. Chimeryczne receptory antygenowe promotora mnd
WO2015182668A1 (ja) * 2014-05-28 2015-12-03 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
DK3151672T3 (da) * 2014-06-06 2021-02-01 Bluebird Bio Inc Forbedrede t-celle-sammensætninger
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EA037271B1 (ru) * 2014-11-06 2021-03-02 Озе Иммьюнотерапьютикс Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге
SMT201900596T1 (it) 2014-12-12 2019-11-13 Bluebird Bio Inc Recettori chimerici di antigene per bcma
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
TWI755157B (zh) 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
PH12021550910A1 (en) * 2015-05-06 2022-03-07 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3307307A4 (en) 2015-06-09 2019-05-01 The Board of Regents of the University of Oklahoma COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE
MX389834B (es) 2015-06-24 2025-03-20 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
HRP20202019T1 (hr) 2015-07-01 2021-04-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA51531A (fr) * 2015-07-06 2020-11-11 Immatics Biotechnologies Gmbh Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI796642B (zh) 2015-08-28 2023-03-21 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
JP7572700B2 (ja) 2015-10-19 2024-10-24 ユニバーシティ オブ メリーランド ボルチモア 改変ヒト初代血液樹状細胞株を生成するための方法
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
HK1255541A1 (zh) * 2015-12-11 2019-08-23 Immatics Biotechnologies Gmbh 用於多种癌症免疫治疗的新型肽和肽组合物
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
WO2017123996A1 (en) 2016-01-15 2017-07-20 City Of Hope Targeting glioblastoma stem cells through the tlx-tet3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
DK3430037T3 (da) 2016-03-16 2022-11-21 Immatics Biotechnologies Gmbh Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
CR20180530A (es) * 2016-04-06 2019-03-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
SI3518948T1 (sl) * 2016-10-03 2023-09-29 Ottawa Hospital Research Institute Kompozicije in metode za povečanje rasti, širjenja ter onkolitične in imunoterapevtske učinkovitosti onkolitičnih RNA-virusov
BR112019009099A2 (pt) 2016-11-04 2019-07-16 Bluebird Bio Inc composições de células t car anti-bcma
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
MX2019007611A (es) * 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
WO2018127787A1 (en) 2017-01-06 2018-07-12 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) * 2017-02-28 2018-08-30 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US11766455B2 (en) * 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
SI3773689T1 (sl) * 2018-04-11 2023-02-28 Enterome S.A. Antigenski peptidi za preprečevanje in zdravljenje raka
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
CN120843603A (zh) 2018-07-11 2025-10-28 布里格姆妇女医院 用于跨血脑屏障递送试剂的方法和组合物
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
WO2020201048A1 (en) 2019-03-29 2020-10-08 Intervet International B.V. Stabilisation of live mollicutes bacteria in a liquid composition
WO2020206385A1 (en) 2019-04-05 2020-10-08 Earli Inc. Improved methods and compositions for synthetic biomarkers
US10937541B2 (en) * 2019-05-28 2021-03-02 PAIGE.AI, Inc. Systems and methods for processing images to prepare slides for processed images for digital pathology
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
CN115279400A (zh) * 2020-01-10 2022-11-01 布里格姆妇女医院 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
WO2021173193A1 (en) * 2020-02-24 2021-09-02 The Regents Of The University Of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113621023A (zh) * 2020-03-18 2021-11-09 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
KR20230006821A (ko) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 변형 b 세포 및 이의 사용 방법
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4158038A4 (en) * 2020-05-26 2024-10-23 University Health Network Combination cytokines for methods and compositions for treating cancer
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3190707A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
WO2022192457A1 (en) * 2021-03-09 2022-09-15 Bostongene Corporation Predicting response to treatments in patients with clear cell renal cell carcinoma
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) * 2022-03-30 2025-07-24 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
KR102907303B1 (ko) 2024-12-23 2025-12-31 전남대학교산학협력단 다중 분기 잠재 확산 모델 기반 초음파 유도 조직 검사 바늘의 경로 및 위치 실시간 검출 장치, 방법
CN120272531B (zh) * 2025-06-10 2025-08-19 鼐济医药科技(杭州)有限公司 一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
WO1998003197A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
AU6240798A (en) 1997-01-15 1998-08-07 Zymogenetics Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
JPH11507845A (ja) * 1997-02-13 1999-07-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経細胞付着分子スプライシング変種
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2002529048A (ja) * 1997-12-02 2002-09-10 メダレツクス・インコーポレーテツド 抗−Ｆｃ受容体結合成分を発現する細胞
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
WO2001055309A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020168711A1 (en) * 2000-01-31 2002-11-14 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2404489A1 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1317275A1 (de) * 2000-09-06 2003-06-11 Müller, Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
WO2002046416A2 (en) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002222108A1 (en) * 2000-12-08 2002-06-18 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
EP1576966A4 (en) * 2002-12-27 2006-07-26 Shenzhen Tsinghua Yuanxing Bio PROCESS FOR PREPARING A VACCINE AND ANTITUMOR VACCINES
AU2004228050A1 (en) 2003-04-04 2004-10-21 Board Of Regents, University Of Texas System Sapphyrins and uses thereof
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
JP4579836B2 (ja) * 2004-01-23 2010-11-10 株式会社グリーンペプタイド 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) * 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
PL1642905T3 (pl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
JP5087925B2 (ja) * 2004-12-07 2012-12-05 東レ株式会社 新規癌抗原ペプチド及びその用途
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
EP1760089B1 (en) * 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
EP2089423B1 (en) * 2006-09-21 2016-10-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CA2700573C (en) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008109757A2 (en) * 2007-03-06 2008-09-12 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CN114057895A (zh) * 2014-05-28 2022-02-18 诺诺公司 TAT-NR2B9c的氯盐
SG11201808629UA (en) 2016-04-21 2018-11-29 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)

Also Published As

Publication number Publication date
NZ603016A (en) 2014-05-30
CY1121258T1 (el) 2020-05-29
KR102392070B1 (ko) 2022-04-29
PT2331118T (pt) 2017-02-06
EP2172211A1 (en) 2010-04-07
CY1123113T1 (el) 2021-10-29
NZ591882A (en) 2012-12-21
EP3120870B1 (en) 2020-04-01
JP5753783B2 (ja) 2015-07-22
PT3132801T (pt) 2020-02-04
US11136352B2 (en) 2021-10-05
RS60386B1 (sr) 2020-07-31
US20100158931A1 (en) 2010-06-24
CA2936869C (en) 2019-08-06
DK3124043T3 (da) 2020-05-04
PT3069728T (pt) 2019-02-13
JP6297632B2 (ja) 2018-03-20
JP6367266B2 (ja) 2018-08-01
DK3132801T3 (da) 2020-02-10
EP2172212B1 (en) 2016-10-05
KR20200085381A (ko) 2020-07-14
PT3124043T (pt) 2020-05-12
HRP20201015T1 (hr) 2020-10-16
ES2770090T3 (es) 2020-06-30
JP6214066B2 (ja) 2017-10-18
ES2819244T3 (es) 2021-04-15
EP3120868A1 (en) 2017-01-25
ES2710608T3 (es) 2019-04-26
EP3111952A1 (en) 2017-01-04
EP3120870A1 (en) 2017-01-25
HRP20160915T1 (hr) 2016-10-07
RS60385B1 (sr) 2020-07-31
PL2331118T3 (pl) 2017-05-31
RS55043B1 (sr) 2016-12-30
US20210238227A1 (en) 2021-08-05
HRP20182151T1 (hr) 2019-02-08
EP2331118A1 (en) 2011-06-15
JP2012504563A (ja) 2012-02-23
HUE047365T2 (hu) 2020-04-28
EP3106175A1 (en) 2016-12-21
HUE051030T2 (hu) 2021-01-28
PL3120870T3 (pl) 2020-07-27
AU2009300088B2 (en) 2014-09-04
US9993540B2 (en) 2018-06-12
PT3120869T (pt) 2020-09-22
CA2739384C (en) 2017-05-02
JP2017000148A (ja) 2017-01-05
HRP20150223T8 (hr) 2015-07-03
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
PT3106175T (pt) 2020-07-01
HRP20200722T1 (hr) 2020-10-16
HRP20201015T8 (hr) 2022-01-21
CY1123098T1 (el) 2021-10-29
HRP20200110T1 (hr) 2020-05-15
SI3106175T1 (sl) 2020-08-31
SI3120868T1 (sl) 2020-08-31
RS60381B1 (sr) 2020-07-31
KR101883426B1 (ko) 2018-07-31
CA2936982C (en) 2019-12-03
US20130004456A1 (en) 2013-01-03
US20160376314A1 (en) 2016-12-29
US10047124B2 (en) 2018-08-14
MX2011003540A (es) 2011-06-20
PT3120870T (pt) 2020-07-01
HUE042115T2 (hu) 2019-06-28
DK3120868T3 (da) 2020-06-22
RS55543B1 (sr) 2017-05-31
DK3069728T3 (en) 2019-02-25
NZ591855A (en) 2012-11-30
US10100085B2 (en) 2018-10-16
US10227381B2 (en) 2019-03-12
PL3124043T3 (pl) 2020-07-27
SI3124043T1 (sl) 2020-07-31
US20160355550A1 (en) 2016-12-08
US20160376317A1 (en) 2016-12-29
TR201900852T4 (tr) 2019-02-21
JP2017023136A (ja) 2017-02-02
HRP20150223T1 (hr) 2015-06-05
HUE029360T2 (en) 2017-02-28
ES2584245T3 (es) 2016-09-26
US20120141517A1 (en) 2012-06-07
US20110002963A1 (en) 2011-01-06
PL2172211T3 (pl) 2015-05-29
CA2739387A1 (en) 2010-04-08
SI3132801T1 (sl) 2020-03-31
SI2331118T1 (sl) 2017-01-31
EA201100586A1 (ru) 2011-10-31
PL3120868T3 (pl) 2020-08-24
US20190010190A1 (en) 2019-01-10
CY1118702T1 (el) 2017-07-12
HUE049366T2 (hu) 2020-09-28
EP3120869B1 (en) 2020-07-22
HUE030296T2 (en) 2017-04-28
CY1123526T1 (el) 2022-03-24
BRPI0920791B8 (pt) 2022-02-15
ES2802227T3 (es) 2021-01-18
US8653035B2 (en) 2014-02-18
CA2936982A1 (en) 2010-04-08
KR20160103558A (ko) 2016-09-01
SI3069728T1 (sl) 2019-03-29
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
US8119139B2 (en) 2012-02-21
HRP20190202T1 (hr) 2019-03-22
PT3111952T (pt) 2019-02-05
CN102170900A (zh) 2011-08-31
KR102133402B1 (ko) 2020-07-14
AU2009300087B2 (en) 2014-09-04
CA2936869A1 (en) 2010-04-08
HUE049367T2 (hu) 2020-09-28
CY1119744T1 (el) 2018-06-27
CA2936870C (en) 2019-11-26
CA2936887A1 (en) 2010-04-08
KR20110082155A (ko) 2011-07-18
KR20180088494A (ko) 2018-08-03
PT3120868T (pt) 2020-07-16
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
DK3111952T3 (en) 2019-01-28
DK2331118T3 (da) 2017-01-09
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
PL2341927T3 (pl) 2016-11-30
EP2172211B1 (en) 2014-12-03
EP3120869A1 (en) 2017-01-25
CA2936920A1 (en) 2010-04-08
NZ624533A (en) 2015-09-25
JP2016145210A (ja) 2016-08-12
PL3132801T3 (pl) 2020-06-15
JP2014239681A (ja) 2014-12-25
KR20220058655A (ko) 2022-05-09
JP6150859B2 (ja) 2017-06-21
CY1116302T1 (el) 2017-02-08
US10919931B2 (en) 2021-02-16
CY1121098T1 (el) 2019-12-11
JP2017018102A (ja) 2017-01-26
CA2936920C (en) 2019-12-03
CA2936870A1 (en) 2010-04-08
US8961985B2 (en) 2015-02-24
DK2341927T3 (en) 2016-08-15
EP2341927B1 (en) 2016-05-04
EP3069728B1 (en) 2018-11-14
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
EP2172212A2 (en) 2010-04-07
EP3124043A1 (en) 2017-02-01
US10047123B2 (en) 2018-08-14
HK1161106A1 (en) 2012-08-24
CA2936868A1 (en) 2010-04-08
DK2172212T3 (da) 2016-12-19
CN106986919A (zh) 2017-07-28
ES2708654T3 (es) 2019-04-10
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
ES2804723T3 (es) 2021-02-09
RS58229B1 (sr) 2019-03-29
LT3132801T (lt) 2020-02-10
KR101756488B1 (ko) 2017-07-11
BRPI0920791B1 (pt) 2022-01-18
EP3120868B1 (en) 2020-04-08
HK1159526A1 (zh) 2012-08-03
EP3132801A1 (en) 2017-02-22
HUE050428T2 (hu) 2020-12-28
US12221493B2 (en) 2025-02-11
US8895514B2 (en) 2014-11-25
PL3106175T3 (pl) 2020-08-24
DK3106175T3 (da) 2020-06-22
CA2936868C (en) 2019-10-22
MX2011003539A (es) 2011-06-20
US20160376316A1 (en) 2016-12-29
US11208434B2 (en) 2021-12-28
CA2739387C (en) 2019-10-29
US20160376313A1 (en) 2016-12-29
JP5883476B2 (ja) 2016-03-15
JP6294913B2 (ja) 2018-03-14
BRPI0920791A2 (pt) 2019-12-10
LT2331118T (lt) 2016-12-27
RS58443B1 (sr) 2019-04-30
JP5855940B2 (ja) 2016-02-09
CN102170901A (zh) 2011-08-31
EA201401104A1 (ru) 2015-05-29
SI3120870T1 (sl) 2020-08-31
EA032437B1 (ru) 2019-05-31
PT2172211E (pt) 2015-03-09
CA2739384A1 (en) 2010-04-08
HRP20201025T8 (hr) 2022-01-07
US10941181B2 (en) 2021-03-09
US10046037B2 (en) 2018-08-14
HRP20200988T1 (hr) 2020-10-16
ES2788129T8 (es) 2020-11-04
PL2172212T3 (pl) 2017-04-28
TR201900809T4 (tr) 2019-02-21
US20150125478A1 (en) 2015-05-07
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
DK3120870T3 (da) 2020-06-22
PT2172212T (pt) 2016-12-22
PL3111952T3 (pl) 2019-04-30
MX338294B (es) 2016-04-11
EP3111952B1 (en) 2018-10-31
HRP20170115T1 (hr) 2017-03-24
CA2936924A1 (en) 2010-04-08
EP3069728A1 (en) 2016-09-21
DK2172211T3 (en) 2015-02-16
LT3120869T (lt) 2020-11-10
CN102170900B (zh) 2016-10-26
US20160376315A1 (en) 2016-12-29
EP3124043B1 (en) 2020-04-29
LT3120868T (lt) 2020-08-10
ES2536465T3 (es) 2015-05-25
CY1123089T1 (el) 2021-10-29
JP2016047825A (ja) 2016-04-07
EA023013B1 (ru) 2016-04-29
PT2341927T (pt) 2016-08-02
JP2017018101A (ja) 2017-01-26
JP2012504393A (ja) 2012-02-23
DK3120869T3 (da) 2020-08-10
UA110599C2 (uk) 2016-01-25
CA2936887C (en) 2019-11-12
AU2009300087A1 (en) 2010-04-08
LT3111952T (lt) 2018-12-27
WO2010037514A2 (en) 2010-04-08
US20210253637A1 (en) 2021-08-19
EP3106175B1 (en) 2020-04-01
WO2010037514A3 (en) 2010-06-03
US20170326217A1 (en) 2017-11-16
CY1122677T1 (el) 2021-03-12
LT3106175T (lt) 2020-08-10
CN102170901B (zh) 2015-01-07
EP2331118B1 (en) 2016-10-26
EP2172212A3 (en) 2010-04-14
RS55531B1 (sr) 2017-05-31
HUE031030T2 (en) 2017-06-28
SI2172212T1 (sl) 2016-12-30
SI3111952T1 (sl) 2019-01-31
SI3120869T1 (sl) 2020-10-30
HUE049364T2 (hu) 2020-09-28
LT3069728T (lt) 2019-02-11
LT2172212T (lt) 2016-11-10
KR101687840B1 (ko) 2016-12-19
US12234298B2 (en) 2025-02-25
ES2607460T3 (es) 2017-03-31
AU2009300088A1 (en) 2010-04-08
JP6294914B2 (ja) 2018-03-14
ES2612466T3 (es) 2017-05-17
CY1122913T1 (el) 2021-10-29
HUE041446T2 (hu) 2019-05-28
WO2010037513A1 (en) 2010-04-08
HRP20161504T1 (hr) 2016-12-30
RS60338B1 (sr) 2020-07-31
US20210347822A1 (en) 2021-11-11
BRPI0920759A2 (pt) 2016-03-08
UA103202C2 (ru) 2013-09-25
CA2936924C (en) 2019-07-16
US10906936B2 (en) 2021-02-02
KR20110074894A (ko) 2011-07-04
EP2341927A2 (en) 2011-07-13
EP3132801B1 (en) 2019-10-30
US8318677B2 (en) 2012-11-27
US20210261614A1 (en) 2021-08-26
JP2017029135A (ja) 2017-02-09
HRP20201228T1 (hr) 2021-02-05
US20130309193A1 (en) 2013-11-21
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30

Similar Documents

Publication Publication Date Title
KR101687840B1 (ko) 아교모세포종(ｇｂｍ) 및 다른 암의 치료를 위한 종양-관련 펩티드 및 관련된 항암 백신의 조성물
TWI533882B (zh) 用於治療胃癌和其他癌症的抗腫瘤相關肽及相關抗癌疫苗組合物
CN101765434B (zh) 抗肿瘤相关肽及相关抗癌疫苗组合物
RS53872B1 (sr) Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
CN103547283A (zh) 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法
Class et al. Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS Inventors: Toni Weinschenk (Aichwald, DE) Oliver Schoor (Tubingen, DE) Oliver Schoor (Tubingen, DE) Claudia Trautwein (Wuelfrath, DE) Claudia Trautwein (Wuelfrath, DE) Norbert Hilf (Kirchentellinsfurt, DE) Norbert Hilf (Kirchentellinsfurt, DE) Steffan Walter (Reutlingen, DE) Harpreet Singh (Tuebingen, DE) Harpreet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH
Class et al. Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCERS Inventors: Jens Fritsche (Tuebingen, DE) Jens Fritsche (Tuebingen, DE) Toni Weinschenk (Aichwald, DE) Steffen Walter (Reutlingen, DE) Steffen Walter (Reutlingen, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Harpeet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH
HK1161106B (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers